OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Target Recruit Count
- 25
- Registration Number
- NCT06740526
- Locations
- 🇺🇸
For Additional Information Regarding Sites Contact 844-687-8522, New York, New York, United States
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
- Conditions
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-07-31
- Target Recruit Count
- 54
- Registration Number
- NCT06372210
- Locations
- 🇺🇸
Research site, Garden Grove, California, United States
A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 60
- Registration Number
- NCT05848700
- Locations
- 🇺🇸
Woodland International Research Group, LLC, Little Rock, Arkansas, United States
🇺🇸Neuro-Behavioral Clinical Research, Inc, North Canton, Ohio, United States
🇺🇸Pillar Clinical Research, LLC, Richardson, Texas, United States
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 434
- Registration Number
- NCT05729373
- Locations
- 🇪🇸
Hospital de Antequera Site#400, Málaga, Spain
🇺🇸University of Alabama at Birmingham Site #116, Huntsville, Alabama, United States
🇺🇸Excell Research, Inc. Site #106, Oceanside, California, United States
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 101
- Registration Number
- NCT05628103
- Locations
- 🇺🇸
Clinical Innovations, Inc, Riverside, California, United States
🇺🇸California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC), San Diego, California, United States
🇺🇸Cenexel CNS Research, Torrance, California, United States
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-05-29
- Target Recruit Count
- 900
- Registration Number
- NCT05593029
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States
A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 19
- Registration Number
- NCT05542264
- Locations
- 🇺🇸
Shari DeSilva, Rogers, Arkansas, United States
🇺🇸Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸Endeavor Clinical Trials, San Antonio, Texas, United States
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-10-24
- Target Recruit Count
- 336
- Registration Number
- NCT05536414
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, Austin, Texas, United States
Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety
A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 15
- Registration Number
- NCT05463770
- Locations
- 🇺🇸
CNRI - San Diego LLC, San Diego, California, United States
🇺🇸Catalina Research Institute LLC, Montclair, California, United States
🇺🇸Pillar Clinical Research, LLC, Richardson, Texas, United States